Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 8/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7347312 | 0.98 | FABP4 (0.38) | FABP4FABP5ALDH1A1CA2CYP1A2 | |
| SCHEMBL30252249 | 0.96 | FABP4 (0.36) | FABP4FABP5ALDH1A1CA2CYP1A2 | |
| SCHEMBL2722431 | 0.91 | CA2 (0.39) | FABP4FABP5ALDH1A1CA2SMN1; SMN2 | |
| SCHEMBL16409213 | 0.80 | CTSL (0.34) | ALDH1A1CA2SMN1; SMN2CTSS | |
| SCHEMBL23794142 | 0.78 | ALDH1A1 (0.36) | FABP4FABP5ALDH1A1CYP1A2ERAP1 | |
| SCHEMBL9947946 | 0.78 | CA2 (0.34) | ALDH1A1CA2SMN1; SMN2POLB | |
| SCHEMBL16391617 | 0.76 | EPHX1 (0.36) | ALDH1A1CA2SMN1; SMN2POLBCTSS | |
| SCHEMBL19388569 | 0.76 | CTSS (0.33) | CA2CTSS | |
| SCHEMBL18125955 | 0.75 | ALDH1A1 (0.41) | FABP4FABP5ALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL16391416 | 0.73 | FABP4 (0.36) | FABP4FABP5ALDH1A1FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20220411462-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-4086272-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-11-09 | — | — | EP | disclosed |
| CN-102076688-A | Purine derivatives further comprising a mercapto-acylamino group as neutral endopeptidase inhibitors | NOVARTIS AG | 2011-05-25 | — | — | CN | disclosed |
| WO-2009138122-A1 | PURINE DERIVATIVES FURTHER COMPRISING A MERCAPTO-ACYLAMINO GROUP AS NEUTRAL ENDOPEPTIDASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-19 | — | — | WO | disclosed |
| EP-0552712-B1 | 8-(1-Aminocycloalkyl)-1,3-dialkylxanthine derivatives as antagonists adenosine receptors | FOSCAMA BIOMED CHIM FARMA (IT) | 1998-11-25 | — | — | EP | disclosed |
| US-5378844-A | ADENOSINE ANTAGONIST | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1995-01-03 | — | — | US | disclosed |
| EP-0552712-A1 | 8-(1-Aminocycloalkyl)-1,3-dialkylxanthine derivatives as antagonists adenosine receptors | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1993-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411462-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | NGLY1, NPPA, VIP | FABP4 2666/4885FABP5 3043/4885ALDH1A1 4672/4885 |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | DNPEP, VIP, NPEPPS | FABP4 3266/4885FABP5 3048/4885ALDH1A1 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.